These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Recent advances in the treatment of Parkinsonism with drugs. Rinne UK. Acta Neurol Scand Suppl; 1972 Sep 05; 51():59-103. PubMed ID: 4576076 [No Abstract] [Full Text] [Related]
9. [Biochemical and clinical correlations in Parkinson's disease]. Barbeau A. Rev Neurol (Paris); 1972 Aug 05; 127(2):253-64. PubMed ID: 4603361 [No Abstract] [Full Text] [Related]
10. Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism. Brogden RN, Speight TM, Avery GS. Drugs; 1971 Aug 05; 2(4):262-400. PubMed ID: 4340597 [No Abstract] [Full Text] [Related]
11. [10 years of L-DOPA therapy of Parkinson's syndrome]. Birkmayer W. Wien Klin Wochenschr; 1971 Apr 02; 83(13):221-7. PubMed ID: 4254333 [No Abstract] [Full Text] [Related]
12. [Treatment of Parkinsonic syndrome with levo-Dopa. Case reports]. Rosati G, Agnetti V, Mura F, Granieri E. Minerva Med; 1974 May 02; 65(33):1811-23. PubMed ID: 4602058 [No Abstract] [Full Text] [Related]
13. L-Dopa in the treatment of parkinsonism. Calne DB. Clin Pharmacol Ther; 1970 May 02; 11(6):789-801. PubMed ID: 4921292 [No Abstract] [Full Text] [Related]
15. Therapeutic uses and side effects of L-dopa. Boshes B. Adv Intern Med; 1972 Apr 04; 18():219-49. PubMed ID: 4576081 [No Abstract] [Full Text] [Related]
16. [Comparison of the effect of L-Dopa and of an L-Dopa+decarboxylase inhibitor combination in Parkinson's disease]. Schneider E, Fischer PA, Jacobi P, Maxion H. Arch Psychiatr Nervenkr (1970); 1973 Mar 19; 217(1):95-112. PubMed ID: 4695662 [No Abstract] [Full Text] [Related]
17. Dopaminergic nervous transmission in Parkinson's disease. Rinne UK, Sonninen V, Riekkinen P, Laaksonen H. Med Biol; 1974 Jun 19; 52(3):208-17. PubMed ID: 4371255 [No Abstract] [Full Text] [Related]
18. Brain catecholamines and their metabolites in Parkinsonian patients. Treatment with levodopa alone or combined with a decarboxylase inhibitor. Rinne UK, Sonninen V. Arch Neurol; 1973 Feb 19; 28(2):107-10. PubMed ID: 4683147 [No Abstract] [Full Text] [Related]
19. [Abnormal movements induced by L-Dopa and dopamine metabolism disorders]. Lhermitte F, Rosa A, Comoy E, Bohuon C. Rev Neurol (Paris); 1973 Dec 19; 129(6):313-24. PubMed ID: 4794176 [No Abstract] [Full Text] [Related]
20. Theoretical implications of the use of L-dopa in parkinsonism. A review. Klawans H, Ilahi MM, Shenker D. Acta Neurol Scand; 1970 Dec 19; 46(4):409-41. PubMed ID: 4323341 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]